Target intelligence / Profile preview

Mycobacterial F-ATP synthase subunit c (atpE)

Target
atpE
Molecular classification
Enzyme, Transporter, F-type ATPase
01

Overview

The mycobacterial F-ATP synthase subunit c is a vital component of the F0 sector of the ATP synthase complex, which is responsible for generating adenosine triphosphate (ATP) in Mycobacterium tuberculosis (Andries et al., 2005). This subunit assembles into a decameric ring structure that functions as a proton-driven rotary motor, coupling the flow of protons across the bacterial membrane to the synthesis of ATP (Preiss et al., 2015). As an essential enzyme for both aerobic respiration and the maintenance of membrane potential in dormant states, it serves as a validated therapeutic target for treating multi-drug-resistant tuberculosis (Koul et al., 2007). The diarylquinoline antibiotic bedaquiline exerts its bactericidal effect by binding to specific residues within the c-ring, effectively jamming the rotor and halting ATP production (Andries et al., 2005). This mechanism is highly selective for mycobacteria over human mitochondrial ATP synthase due to structural differences in the binding pocket, minimizing off-target effects in patients (Haagsma et al., 2009).

Other names
ATP synthase subunit cF-type H+-transporting ATPase subunit cSubunit c of F1F0-ATP synthaseatpEMycobacterial F-ATP synthase c-ring
02

Mechanism of action

Bedaquiline binds to the c-ring of the F0 rotor of mycobacterial ATP synthase, specifically interacting with residues such as Glu61 and Tyr64, which physically blocks the rotation of the enzyme and inhibits the proton pump mechanism, leading to the depletion of cellular ATP levels and subsequent bacterial death (Andries et al., 2005; Preiss et al., 2015).

03

Biological functions

ATP synthesisProton transportEnergy metabolismOxidative phosphorylation
04

Disease associations

InfectionTuberculosis
05

Safety considerations

Development of antimicrobial resistance through atpE or mmpR mutations (Segala et al., 2017)Potential for QTc interval prolongation (associated with bedaquiline therapy) (FDA, 2012)Selectivity concerns regarding human mitochondrial ATP synthase, although structural differences minimize this risk (Haagsma et al., 2009)
06

Interacting drugs

Bedaquiline
07

Biomarkers

atpE gene mutations (e.g., Ala63Pro, Ile66Met)mmpR (Rv0678) mutations

Beyond the preview

Go deeper on Mycobacterial F-ATP synthase subunit c (atpE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mycobacterial F-ATP synthase subunit c (atpE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call